DocMorris AG

ROSE

CH0042615283

Drug Retailers

Market Closed - Swiss Exchange Other stock markets 11:30:08 2024-07-17 am EDT			5-day change	1st Jan Change
46 ^CHF	-2.50%		-20.76%	-37.63%

12:28pm	DOCMORRIS : Warburg Research reaffirms its Buy rating	ZD
Jul. 12	DOCMORRIS : Hauck & Aufhauser reaffirms its Buy rating	ZD

ZUR ROSE GROUP : UBS gives a Sell rating

January 21, 2022 at 05:33 am EST

In a research note published by Sebastian Vogel, UBS advises its customers to Sell the stock. The target price is unchanged and still at CHF 250.

Latest news about DocMorris AG

DOCMORRIS : Warburg Research reaffirms its Buy rating	06:28am	ZD
DOCMORRIS : Hauck & Aufhauser reaffirms its Buy rating	Jul. 12	ZD
DOCMORRIS : Deutsche Bank reiterates its Buy rating	Jul. 12	ZD
DOCMORRIS : Warburg Research maintains a Buy rating	Jul. 11	ZD
DOCMORRIS : Sell rating from UBS	Jul. 11	ZD
DocMorris' H1 Revenue Grows; FY24 Outlook Affirmed	Jul. 11	MT
Redcare continues to recover - business with e-prescription picks up	Jul. 04	DP
DOCMORRIS : Jefferies keeps its Buy rating	Jul. 02	ZD
DOCMORRIS : Gets a Buy rating from Jefferies	Jun. 19	ZD
DOCMORRIS : Jefferies gives a Buy rating	Jun. 05	ZD
DOCMORRIS : Receives a Sell rating from UBS	Jun. 04	ZD
Warburg: Several mid-caps attractive takeover targets - and Mercedes-Benz	May. 27	DP
DOCMORRIS : Warburg Research reiterates its Buy rating	May. 27	ZD
Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney...	May. 23
DOCMORRIS : Gets a Buy rating from Baader Bank	May. 22	ZD
UBS sends Redcare and DocMorris share prices plummeting	May. 21	DP
DOCMORRIS : Gets a Sell rating from UBS	May. 21	ZD
DOCMORRIS : Sell rating from UBS	May. 16	ZD
DocMorris Names Successor to Outgoing CFO	May. 08	MT
DocMorris Launches Tender Offer for Convertible Bonds Due 2025	May. 06	MT
ROUNUP: E-prescription advertising squeezes profit margin of online pharmacy Redcare	Apr. 25	DP
DOCMORRIS : Deutsche Bank remains its Buy rating	Apr. 23	ZD
DOCMORRIS : Hauck & Aufhauser gives a Buy rating	Apr. 19	ZD
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	Apr. 18
DOCMORRIS : Gets a Buy rating from Warburg Research	Apr. 18	ZD

Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.

Sector

Drug Retailers

Calendar

2024-08-20 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for DocMorris AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

47.18 CHF

Average target price

88.5 CHF

Spread / Average Target

+87.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
DOCMORRIS AG	-37.63%	679M
WALGREENS BOOTS ALLIANCE, INC.	-54.62%	10.13B
JD HEALTH INTERNATIONAL INC.	-44.50%	8.54B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-19.34%	6.49B
MATSUKIYOCOCOKARA & CO.	-3.00%	6.29B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+92.00%	5.25B
NAHDI MEDICAL COMPANY	-2.48%	4.61B
CLICKS GROUP LIMITED	+6.16%	4.55B
YIFENG PHARMACY CHAIN CO., LTD.	-31.43%	3.72B
REDCARE PHARMACY NV	+6.00%	3.1B

Other Drug Retailers

DocMorris AG

Equities

ROSE

CH0042615283

Drug Retailers

ZUR ROSE GROUP : UBS gives a Sell rating

Latest news about DocMorris AG

Chart DocMorris AG

Company Profile

Income Statement Evolution

Ratings for DocMorris AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Drug Retailers